New drug
Glycopyrronium cream for primary axillary hyperhidrosis
- Aust Prescr 2026;49:258-9
- 1 December 2026
- DOI: 10.18773/austprescr.2026.055
Background: Hyperhidrosis is excessive sweating beyond what is necessary for thermoregulation. Primary hyperhidrosis is idiopathic and commonly affects the axillae (armpits), palms, soles and face. Severe primary hyperhidrosis can be debilitating and have significant psychosocial impact.1
Primary axillary hyperhidrosis is usually first managed with topical antiperspirants that contain aluminium salts. For severe disease, botulinum toxin A injections or oral anticholinergics (e.g. oxybutynin, propantheline) may be used. Sweat-reduction devices or surgery may be considered if pharmacotherapy is ineffective.2
Glycopyrronium cream is the first topical drug treatment approved in Australia for primary axillary hyperhidrosis.
Mechanism of action: Glycopyrronium is an anticholinergic drug that competitively inhibits muscarinic acetylcholine receptors. Sweat glands are normally activated by acetylcholine acting on muscarinic receptors. By blocking these receptors, glycopyrronium reduces sweat production.
Clinical trials: Glycopyrronium cream was evaluated in a phase 3 randomised, double-blind, placebo-controlled trial involving 171 people aged 18 to 65 years with severe primary axillary hyperhidrosis (Hyperhidrosis Disease Severity Scale [HDSS] patient-reported score of 3 or 4).3 Patients who had undergone surgery or received botulinum toxin for hyperhidrosis in the preceding 4 months were excluded.
Patients were randomised to receive glycopyrronium cream or matching placebo, applied once daily to both armpits for 4 weeks. A dispenser was used to deliver a fixed quantity of cream (4.4 mg glycopyrronium per dose in the treatment group). The primary endpoint was the absolute change in sweat production (measured over 5 minutes at a standardised temperature and humidity using absorbent paper).3
Glycopyrronium treatment resulted in a greater reduction in mean sweat production than placebo (−197.08 mg versus −83.49 mg). More patients treated with glycopyrronium achieved a 50% reduction in sweating compared with placebo-treated patients (57% versus 34%).3
After 4 weeks of treatment, a greater proportion of glycopyrronium- than placebo-treated patients achieved a clinically meaningful improvement in quality of life (60% versus 26%), based on the Hyperhidrosis Quality of Life Index score. Patient-reported disease severity (HDSS) improved, although statistical significance was not reached.3
In an open-label extension study, after 4 weeks of daily dosing, patients were advised to use the cream flexibly, from a minimum of twice weekly to a maximum of once daily. At week 12, glycopyrronium was associated with a statistically significant reduction in sweat production and improvements in quality of life scores.4
Adverse effects: Anticholinergic adverse effects were common, including dry mouth (16% glycopyrronium versus 4% placebo),3 which improved over time with continued treatment,4 dry nose (2% glycopyrronium versus 0% placebo) and constipation (1% glycopyrronium versus 0% placebo).3 Local skin reactions (e.g. dermatitis, erythema, papules) occurred at similar rates in both groups.
Dosage and administration: The recommended dose is 2 pump actuations per armpit (4.4 mg glycopyrronium). For the first 4 weeks, the cream should be applied once a day, preferably in the evening. From the fifth week, the frequency of application may be reduced to twice weekly, depending on treatment response.
The pump must be primed before first use. To administer a dose, the cream is pumped onto the top of the container cap, which is then used to apply the cream to the armpit. The cap and hands should be washed after each administration.
Patients should be advised to avoid skin-to-skin contact with other people after application by covering the treated area (e.g. with clothing).
Precautions: The anticholinergic effects of glycopyrronium may exacerbate some pre-existing medical conditions, including glaucoma, cardiac arrhythmias, coronary artery disease, congestive heart failure and severe ulcerative colitis (for a complete list, refer to the approved product information).5
Glycopyrronium should be used with caution in patients with urinary outflow obstruction (e.g. severe prostatic hyperplasia, bladder neck obstruction) or a history of urinary retention. Patients should be advised to stop treatment and seek medical advice if urinary retention occurs.
Reduced sweating may increase the risk of heat-related illness during hot weather, fever or strenuous physical activity. Glycopyrronium should be stopped if patients experience a generalised absence of sweating in hot conditions.
Because glycopyrronium may cause dry mouth, it can increase the risk of dental caries; good oral hygiene and regular dental check-ups are recommended.
Use in pregnancy and breastfeeding: Glycopyrronium cream may be considered during pregnancy; however, human safety data are limited.
Systemic glycopyrronium has been shown to be excreted into animal milk and may suppress lactation; however, the risk after topical application is low. To minimise infant exposure, direct contact between the infant and treated skin should be avoided. A decision should be made to stop either breastfeeding or glycopyrronium therapy, considering the benefits of breastfeeding for the infant and the benefits of treatment for the mother.5
Place in therapy: Glycopyrronium cream provides a treatment option for adults with severe primary axillary hyperhidrosis who have not responded to, or are intolerant of, topical aluminium-based antiperspirants. Previously, the main treatment alternatives were botulinum toxin A injections, which require administration by a dermatologist or neurologist, and oral anticholinergics, which are associated with a greater risk of systemic adverse effects. No clinical trials have directly compared topical glycopyrronium with botulinum toxin A or oral anticholinergics; however, indirect comparisons suggest that topical glycopyrronium may be less effective.6
In Australia, glycopyrronium cream can be prescribed by a general practitioner and is subsidised through the Pharmaceutical Benefits Scheme, potentially improving treatment accessibility and reducing costs compared with botulinum toxin A injections.
Practice points: Assess for tachycardia before starting treatment as glycopyrronium may increase heart rate.
Monitor for, and counsel patients on, anticholinergic effects, particularly urinary retention, dry mouth and blurred vision.
Advise patients about the increased risk of heat exhaustion or heatstroke, particularly during hot weather or strenuous physical activity.
Advise patients to have regular dental check-ups due to the increased risk of dental caries.
This new drug comment was finalised on 29 October 2026. It was prepared by Sherilyn Wong, Clinical Editor, Australian Prescriber, and reviewed by Amy Legg, Clinical Pharmacist, Queensland Statewide Antimicrobial Stewardship Program.
At the time this new drug comment was prepared, the Australian Public Assessment Report was not available from the Therapeutic Goods Administration. The sponsor did not provide the Clinical Evaluation Report.
This article is peer reviewed.
Australian Prescriber welcomes Feedback.
The new drug comments in Australian Prescriber are prepared by the editors and reviewed by subject matter experts. Some of the views expressed on newly approved products should be regarded as preliminary, as there may be limited published data at the time of publication, and little experience in Australia of their safety or efficacy. Before new drugs are prescribed, it is important that more detailed information is obtained from the approved product information, a medicines information centre or some other appropriate source.
Report all suspected adverse reactions to new drugs to enable continued monitoring of their benefit–harm balance.